INTERVENTIONAL ONCOLOGY CORPORATE AND REGIONAL PRESS RELEASES

Please find below a list of our press releases.

21 Feb 2018

First Patient in Latin America Receives TheraSphere® Radioembolisation Treatment

February 28, 2018: BTG plc (LSE: BTG), a global specialist healthcare company, announced the first patient in Latin America in Mexico was treated with TheraSphere® – a treatment for hepatic neoplasia that delivers powerful radiation to tumour cells and minimizes the exposure to healthy tissue.

6 Feb 2018

OPTALYSE PE Long Term Results Reinforce Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism

BTG plc (LSE: BTG), the global healthcare company, today highlighted OPTALYSE PE one year trial results, presented at the International Society on Endovascular Therapy in Florida.

11 Dec 2017

Institutional Decision to Adopt Y90 TARE with TheraSphere® as first-line treatment for HCC

Based on experience with 1000 patients over 15 years, the largest single-centre, prospective centre cohort of patients with HCC treated with Y90 glass microspheres

5 Oct 2017

BTG plc acquires Roxwood Medical

London, UK, 5 October 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.

27 Sep 2017

Mirada Medical signs three-year software development agreement with BTG

Mirada Medical Ltd, a global medical imaging software company, has signed a three-year master service agreement with BTG plc (LSE: BTG), a global specialist healthcare company. The agreement covers multiple software development projects to support BTG’s portfolio of interventional medicine products.

21 Aug 2017

BTG and SIO expand Immuno-Oncology / Interventional Oncology grant programme

BTG plc (LSE: BTG), a global specialist healthcare company, and the Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, have expanded their commitment to the Immuno-Oncology / Interventional Oncology research grant programme, by announcing a second round of funding available to investigators.

5 Dec 2016

PneumRx® Coils included in new global clinical guidelines and given positive recommendation to treat severe emphysema patients in France

BTG plc (LSE: BTG), the global specialist healthcare company, today announces the inclusion of treatment with PneumRx® Coils in guidelines for the management of chronic obstructive pulmonary disease (COPD) published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).

5 Dec 2016

Le Canada, premier pays à bénéficier d’une nouvelle option de traitement contre le cancer du foie

Les microsphères radio-opaques à élution médicamenteuse DC Bead LUMIMC offrent aux radiologistes interventionnels du Canada un traitement de nouvelle génération pour les patients atteints d’un cancer du foie

14 Oct 2016

BTG and Mirada Medical announce CE Mark Certification for Simplicit Y90 dosimetry software in Europe

New easy-to-use software designed to improve the planning of Y90 selective internal radiation therapy (SIRT) treatment for patients with liver cancer

BTG plc (LSE: BTG), an international specialist healthcare company, with Mirada Medical Ltd, a leading global brand in medical imaging software, today announced CE Mark certification for Simplicit Y90™ dosimetry software, designed to optimise the planning of Y90 selective internal radiation therapy (SIRT) and facilitate personalised treatment for patients with liver cancer. CE Mark certification follows approval for Simplicit Y90™ in Canada.

15 Jun 2016

BTG completes the acquisition of Galil Medical

BTG completes the acquisition of Galil Medical